EHC vs TECH

EHC presents a stable financial profile with a Piotroski F-Score of 4/9 and a significant valuation gap between its defensive Graham Number ($55.18) and growth-based Intrinsic Value ($163.72). The company exhibits exceptional operational efficiency with an ROE of 24.82% and a highly attractive PEG ratio of 0.41, suggesting the stock is undervalued relative to its earnings growth. While insider sentiment is bearish and technical trends are currently weak, the long-term fundamental trajectory is supported by a 25-quarter track record of consistent earnings beats. The current price of $101.98 represents a reasonable entry point given the analyst target of $142.73.

Bio-Techne exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a very low Debt/Equity ratio of 0.17. However, there is a massive disconnect between the current price ($60.58) and deterministic value metrics, such as the Graham Number ($12.40) and Intrinsic Value ($10.94). While the PEG ratio of 0.76 and forward P/E of 27.99 suggest growth potential that justifies a premium, stagnant revenue growth (-0.40%) and bearish technical trends temper the outlook. The stock is a high-quality company trading at a significant growth premium.